HC Wainwright & Co. Maintains Buy on Panbela Therapeutics, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Panbela Therapeutics (PBLA) but lowers the price target from $16 to $5.
April 02, 2024 | 12:49 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Panbela Therapeutics' price target was reduced from $16 to $5 by HC Wainwright & Co., although the Buy rating was maintained.
The significant reduction in the price target from $16 to $5, despite maintaining a Buy rating, could indicate concerns about Panbela Therapeutics' future performance or market conditions, potentially leading to short-term negative sentiment among investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100